X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the partnership, Zhifei will co-promote GSK’s shingles vaccine, Shingrix (recombinant zoster vaccine or RZV), a non-live, recombinant subunit vaccine in China for an initial three-year period.
Lead Product(s): Adjuvanted Recombinant Zoster Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Shingrix
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: GSK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 09, 2023
Details:
Under the collaboration, Zhifei will continue to purchase five vaccine products including, 4-valent and 9-valent HPV vaccine, Gardasil (recombinant human papillomavirus quadrivalent vaccine), pentavalent rotavirus vaccine and other agreed products from MSD.
Lead Product(s): Recombinant Human Papillomavirus Quadrivalent Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Gardasil
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $14,800.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 21, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
